Abstract:Recurrent spontaneous abortion is one of the common complications in women of childbearing age during pregnancy. The immune factor accounts for a large proportion of many causes. Antiphospholipid antibody syndrome is the most common type of acquired thrombophilia disease. Autoimmune diseases that cause thrombosis and obstetric complications under the action of antibodies are also the most common type of immune-related recurrent abortion. At present, there is no unified opinion on the treatment of this disease, especially the treatment of immunoglobulins and other drugs like glucocorticoid. Here we reviewed the progress of diagnosis and treatment of antiphospholipid antibody-related recurrent abortions and retrospectively analyzed and summarized the drug regimens and pregnancy outcomes of this disease with pregnancy patients in our hospital. A total of 75 patients were included. According to their clinical manifestations and laboratory results, these patients were basically divided into two categories: classical antiphospholipid syndrome and non-classical antiphospholipid syndrome. The latter was further divided into serum-negative antiphospholipid syndrome and antiphospholipid antibody-related recurrent abortion patients based on their clinical manifestations and antiphospholipid antibody results. The patients were divided into four categories: aspirin + hydroxychloroquine, aspirin + low molecular weight heparin, aspirin + low molecular weight heparin + hydroxychloroquine, aspirin + hydroxychloroquine + low molecular weight heparin + low dose glucocorticoids. Among them, aspirin + hydroxychloroquine + low molecular weight heparin + low dose glucocorticoid treatment regimen was most commonly used. Most of the patients who received the above different treatment regimens achieved full-term infants, and a small number of patients had adverse pregnancy outcomes, such as premature delivery, placental abruption, eclampsia, and fetal malformation. And adverse pregnancy outcomes also occurred in this group. It might be related to the severity of the disease and the potential adverse effects of maternal fetal. However, further statistical analysis is needed for the risk factors affecting the pregnancy outcome of this part of patients.

Review of Updated Methods of Diagnosis and Management of Antiphospholipid Syndrome

Review of Antiphospholipid Syndrome and Its Cardiovascular Manifestation

An Update on Antiphospholipid Syndrome

Antiphospholipid Syndrome: a Survey of Clinical Characters in Ten Cases

Clinical and Laboratory Diagnosis of Antiphospholipid Syndrome: A Review

Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management

Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review

An update on inflammation in antiphospholipid syndrome

Antiphospholipid Syndrome in Pregnancy: New and Old Pathogenetic Mechanisms

Antiphospholipid Syndrome: a Clinical Perspective

Obstetric antiphospholipid syndrome: A recent classification for an old defined disorder

Viewpoint: The value of non-criteria antiphospholipid antibodies

[Diagnosis and treatment of antiphospholipid antibody-related recurrent spontaneous abortion and analysis of therapeutic drugs and pregnancy outcome in 75 patients with antiphospholipid syndrome].

[Analysis of Risk Factors in Development of Thrombosis in Patients with Antiphospholipid Syndrome].

Biochemical and clinical predictors in pregnant women with antiphospholipid syndrome and systemic lupus erythematosus: comprehensive update

Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome

Obstetric Antiphospholipid Syndrome: An Update on Pathophysiology and Management

The Issue of the Antiphospholipid Antibody Syndrome

An advanced understanding of the heterogeneous clinical features of “non-criteria” obstetric antiphospholipid syndrome: Two case reports and a literature review

Obstetric Anti-phospholipid Syndrome: State of the Art

16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends